BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32144623)

  • 1. Promoter DNA Hypermethylation of the Cysteine Dioxygenase 1 (CDO1) Gene in Intraductal Papillary Mucinous Neoplasm (IPMN).
    Fujiyama Y; Kumamoto Y; Nishizawa N; Nakamoto S; Harada H; Yokota K; Tanaka Y; Igarashi K; Oiki H; Okuwaki K; Iwai T; Kajita S; Takahashi H; Tajima H; Kaizu T; Sasaki J; Watanabe M; Yamashita K
    Ann Surg Oncol; 2020 Oct; 27(10):4007-4016. PubMed ID: 32144623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (CDO1) promoter DNA in pancreatic cancer.
    Nishizawa N; Harada H; Kumamoto Y; Kaizu T; Katoh H; Tajima H; Ushiku H; Yokoi K; Igarashi K; Fujiyama Y; Okuwaki K; Iwai T; Watanabe M; Yamashita K
    Cancer Sci; 2019 Sep; 110(9):2846-2855. PubMed ID: 31325200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of promoter DNA hypermethylation of the cysteine dioxygenase 1 (CDO1) gene in primary gallbladder cancer and gallbladder disease.
    Igarashi K; Yamashita K; Katoh H; Kojima K; Ooizumi Y; Nishizawa N; Nishiyama R; Kawamata H; Tajima H; Kaizu T; Kumamoto Y; Watanabe M
    PLoS One; 2017; 12(11):e0188178. PubMed ID: 29161283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-specific promoter DNA methylation of Cysteine dioxygenase type 1 (CDO1) gene as an important prognostic biomarker of gastric cancer.
    Harada H; Hosoda K; Moriya H; Mieno H; Ema A; Ushiku H; Washio M; Nishizawa N; Ishii S; Yokota K; Tanaka Y; Kaida T; Soeno T; Kosaka Y; Watanabe M; Yamashita K
    PLoS One; 2019; 14(4):e0214872. PubMed ID: 30934021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter DNA methylation of CDO1 gene and its clinical significance in esophageal squamous cell carcinoma.
    Ushiku H; Yamashita K; Katoh H; Ema A; Minatani N; Kikuchi M; Kojo K; Yokoi K; Tanaka T; Nishizawa N; Ishii S; Hosoda K; Moriya H; Mieno H; Katada N; Kikuchi S; Watanabe M
    Dis Esophagus; 2017 Feb; 30(2):1-9. PubMed ID: 27629777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Significance of Promoter DNA Hypermethylation of cysteine dioxygenase 1 (CDO1) Gene in Primary Breast Cancer.
    Minatani N; Waraya M; Yamashita K; Kikuchi M; Ushiku H; Kojo K; Ema A; Nishimiya H; Kosaka Y; Katoh H; Sengoku N; Tanino H; Sidransky D; Watanabe M
    PLoS One; 2016; 11(1):e0144862. PubMed ID: 26785325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of promoter hypermethylation in malignant risk stratification of intraductal papillary mucinous neoplasms.
    Chhoda A; Sharma A; Sailo B; Tang H; Ruzgar N; Tan WY; Ying L; Khatri R; Narayanan A; Mane S; De Kumar B; Wood LD; Iacobuzio-Donahue C; Wolfgang CL; Kunstman JW; Salem RR; Farrell JJ; Ahuja N
    Clin Epigenetics; 2023 Feb; 15(1):28. PubMed ID: 36803844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
    Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
    Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA expression signatures in intraductal papillary mucinous neoplasm of the pancreas.
    Lubezky N; Loewenstein S; Ben-Haim M; Brazowski E; Marmor S; Pasmanik-Chor M; Oron-Karni V; Rechavi G; Klausner JM; Lahat G
    Surgery; 2013 May; 153(5):663-72. PubMed ID: 23305591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor II messenger RNA-binding protein-3 is a valuable diagnostic and prognostic marker of intraductal papillary mucinous neoplasm.
    Morimatsu K; Aishima S; Yamamoto H; Hayashi A; Nakata K; Oda Y; Shindo K; Fujino M; Tanaka M; Oda Y
    Hum Pathol; 2013 Sep; 44(9):1714-21. PubMed ID: 23597774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
    Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
    Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylated promoter DNA of CDO1 gene and preoperative serum CA19-9 are prognostic biomarkers in primary extrahepatic cholangiocarcinoma.
    Nakamoto S; Kumamoto Y; Igarashi K; Fujiyama Y; Nishizawa N; Ei S; Tajima H; Kaizu T; Watanabe M; Yamashita K
    PLoS One; 2018; 13(10):e0205864. PubMed ID: 30325974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic alterations in adenoma-carcinoma sequencing of intraductal papillary-mucinous neoplasm of the pancreas.
    Nakata B; Yashiro M; Nishioka N; Aya M; Yamada S; Takenaka C; Ohira M; Ishikawa T; Nishino H; Wakasa K; Hirakawa K
    Int J Oncol; 2002 Nov; 21(5):1067-72. PubMed ID: 12370756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasive, mixed-type intraductal papillary mucinous neoplasm: superior prognosis compared to invasive main-duct intraductal papillary mucinous neoplasm.
    Ceppa EP; Roch AM; Cioffi JL; Sharma N; Easler JJ; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    Surgery; 2015 Oct; 158(4):937-44; discussion 944-5. PubMed ID: 26173683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnostic efficacy for predicting intraductal papillary mucinous neoplasms of the pancreas with high grade dysplasia or invasive carcinoma based on the surgery indications in different guidelines].
    Li B; Guo SW; Shi XH; Shen S; Zhang GX; Gao SZ; Pan YQ; Xu XF; Jin G
    Zhonghua Wai Ke Za Zhi; 2021 May; 59(5):359-365. PubMed ID: 33915626
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas.
    House MG; Guo M; Iacobuzio-Donahue C; Herman JG
    Carcinogenesis; 2003 Feb; 24(2):193-8. PubMed ID: 12584167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant methylation of secreted apoptosis-related protein 2 (SARP2) in pure pancreatic juice in diagnosis of pancreatic neoplasms.
    Watanabe H; Okada G; Ohtsubo K; Yao F; Jiang PH; Mouri H; Wakabayashi T; Sawabu N
    Pancreas; 2006 May; 32(4):382-9. PubMed ID: 16670620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
    Ozaki N; Ohmuraya M; Ida S; Hashimoto D; Ikuta Y; Chikamoto A; Hirota M; Baba H
    J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):620-7. PubMed ID: 23475261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical strategy for intraductal papillary mucinous neoplasms of the pancreas.
    Hirono S; Yamaue H
    Surg Today; 2020 Jan; 50(1):50-55. PubMed ID: 31807871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sonic hedgehog is an early developmental marker of intraductal papillary mucinous neoplasms: clinical implications of mRNA levels in pancreatic juice.
    Ohuchida K; Mizumoto K; Fujita H; Yamaguchi H; Konomi H; Nagai E; Yamaguchi K; Tsuneyoshi M; Tanaka M
    J Pathol; 2006 Sep; 210(1):42-8. PubMed ID: 16794990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.